The new drug 'lisdexamfetamine dimesylate' will be available under the brand name Vyvanse, US-based The Obesity Society (TOS) said in a statement.

BED is an eating disorder that affects only a portion of those with the medical disease obesity. While as many as 30 percent of people seeking obesity treatment may report some degree of binge eating, those who meet clinical criteria for BED are likely to represent only 7-10 percent of all obesity treatment seekers.

"It is important to consider treating BED in the context of other treatments specifically targeting obesity," said Susan L McElroy, TOS member who specializes in both obesity and BED treatment.

Latest News from Lifestyle News Desk